Monday, 11 Dec 2017

You are here

Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis

The NEJM reports success when using mepolizumab (anti-IL-5 monoclonal antibody) in a 52 week study of patients with eosinophilic granulomatosis with polyangiitis (EGPA).

EGPA, previously known as Churg-Strauss vasculitis is an eosinophilic vasculitis that has often been managed as other systemic necrotizing vasculitis.  Given the eosinophilic component, Weschler and coworkers studied the efficacy and safety of mepolizumab, an anti–interleukin-5 monoclonal antibody, in EGPA.

The NEJM reports on a 136 patients study with relapsing or refractory EGPA patients on stable doses of steroids were randomized to either 300 mg of mepolizumab or placebo, administered subcutaneously every 4 weeks, for 52 weeks. The two primary end points were the accrued weeks of remission over a 52-week period, and the remission rates at both week 36 and week 48.

The mepolizumab were 6 times more likely to have more accrued more weeks of remission than placebo (28% vs. 3%).

The anti-IL-5 mAb also had a higher percentage of remissions at both week 36 and week 48 (32% vs. 3%).  Non-remission was seen in 47% on mepolizumab compared to 81% on placebo.

The annualized relapse rate 50% lower in the mepolizumab group, compared to the placebo group and there was less steroid use in the active treatment group, with 18% of the mepolizumab patients being able to discontinue prednisone completely..

Although only half the participants treated with mepolizumab had protocol-defined remission, this novel biologic intervention represents a new and significant advance in the treatment of EGPA.

An accompanying NEJM editorial by Drs.Djukanovic and O'Byrnes (http://buff.ly/2qW3qsJ) commented "Although the trial was powered to evaluate relapses on the basis of a worsening condition in any of three categories (asthma, vasculitis, and sinonasal disease alone or in combination), the benefit of treatment was slightly greater with regard to relapses defined according to exacerbating asthma-based or sinonasal-based symptoms. This finding suggests that the vasculitic component of eosinophilic granulomatosis with polyangiitis may respond less well to mepolizumab than do other components of the disease."   They comment that additional trials with this agent are needed and that further study of its possible synergism azathioprine, cyclophosphamide or other immunosuppressants would be welcomed..

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?

Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi). (Citation source: https://buff.ly/2zXyY2X)

BMS Featured Presentations from ACR 2017

Bristol-Myers Squibb Company confirmed that 34 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting, November 3-8, 2017, in San Diego.

Biosimilars Projected to Yield $54 Billion in Savings

A primary projected advantage to biosimilar drugs development has been cost savings. A new study from the RAND Corporation suggests biosimilars could cut health care spending in the United States by $54 billion over the next decade. This number is nearly 20 percent greater than a similar study conducted three years ago by the same researchers. 

Patterns of Biologic Use During Autoimmune Pregnancy

While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.

Sirukumab Turned Down by FDA

On Friday the U.S. Food and Drug Administration announced that will not approve Johnson & Johnson’s rheumatoid arthritis drug sirukumab, stating further data and study would be needed to establish its safety.